COMMUNIQUÉS West-GlobeNewswire

MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference
14/03/2018
WESTLAKE VILLAGE, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD ) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as [...]
Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference
14/03/2018
NEW HAVEN, Conn., March 14, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT ), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, [...]
RavenQuest Announces Dr. Simerjeet Kaur Will Lead Scientific Research & Development
14/03/2018
VANCOUVER, British Columbia, March 14, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) is pleased to announce it has appointed Dr. Simerjeet Kaur, PhD, to lead Scientific [...]
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
14/03/2018
WALTHAM, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO ), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular [...]
Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients
14/03/2018
Data from the combined first two low dose inarigivir cohorts at weeks 12 and 24 with sequential Viread dosing demonstrate significant reductions in HBV DNA, HBV RNA and HBsAg Data to be presented at the APASL 2018 [...]
Clifford Sarkin Appointed to Millennium BlockChain Board of Advisors
14/03/2018
SANTA MONICA, CA, March 14, 2018 (GLOBE NEWSWIRE) -- Millennium BlockChain Inc. (OTC: MBLC ; the “Company”) is pleased to announce that Clifford Sarkin has joined the Company’s board of advisors. Sarkin is a strategic [...]
Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection
14/03/2018
PLYMOUTH MEETING, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis B virus (HBV) [...]
New Data Showing Patient Care Individualized by Daxor’s Precision Blood Volume Analysis Reduces Heart Failure Readmissions by 56% and Mortality by over 80% Presented at the American College of Cardiology 2018 Annual Scientific Session
14/03/2018
(NYSE MKT LLC: DXR) New York, NY, March 14, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) , an investment company with medical instrumentation and biotechnology operations, announces the presentation of new [...]
FDA Acceptance of IND for Tyme to Begin Phase II Trial in Pancreatic Cancer
14/03/2018
Initial Clinical Sites Expected to Open Over the Coming Weeks NEW YORK, March 14, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME ) (“Tyme” or the “Company”) announced today that the U.S. Food and Drug [...]
K2M Launches Next-Generation YUKON™ OCT Spinal System at AANS/CNS 2018
14/03/2018
LEESBURG, Va., March 14, 2018 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (NASDAQ: KTWO ) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three- [...]
Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
14/03/2018
PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX ), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for AG200-15 (Twirla ® ), [...]
Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
14/03/2018
Initiated final testing of safety and efficacy in non-human primates (NHP) for our lead program intended to treat patients with transthyretin amyloidosis (ATTR) Completed successful knockout editing in mice of the [...]
Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs
14/03/2018
Dr. Rowlands joins Actinium with almost two decades of experience as a regulatory affairs strategist specialized in the development of first-in-class therapeutics for the treatment of rare and/or serious conditions with [...]
Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis
14/03/2018
SHANGHAI, China and CUPERTINO, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG ) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of [...]
Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
14/03/2018
VY-AADC for advanced Parkinson’s disease on track for start of planned global, pivotal Phase 2-3 program during the middle of this year Two IND filings expected from the ALS, Huntington’s disease and Friedreich’s ataxia [...]
Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference
14/03/2018
Summit Therapeutics plc ("Summit" or the "Company") Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference Oxford, UK, and Cambridge, MA, US, 14 March 2018 - Summit [...]
ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference
14/03/2018
YONKERS, New York, March 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX ), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life [...]
Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases
14/03/2018
UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS ), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
Easton Pharmaceuticals Announces It Has Commenced Negotiations With An AMPR Applicant Towards a Marijuana Cultivators / Growers License For Canada; Provides iBliss Update
14/03/2018
TORONTO, ON, March 14, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals Inc. (OTC: EAPH) announces it has commenced negotiations with an AMPR applicant towards a Canadian Marijuana cultivators / growers license. Provides [...]

Pages